At present, two drugs have been approved in the United States for people with early Alzheimer’s disease: donanemab and lecanemab. Unlike older drugs, which only addressed symptoms, the new options target and remove beta-amyloid, thought to be the principal culprit of cognitive impairment, from the brain. While they don’t offer a cure, they slow down cognitive decline.

Full Story